Search

REVOLUTION Medicines Inc

Закрыт

СекторЗдравоохранение

195.62 1.21

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

181

Макс.

194

Ключевые показатели

By Trading Economics

Доход

-89M

-454M

Прибыль на акцию

-2.29

Сотрудники

883

EBITDA

-89M

-437M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+10.23% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

8.5B

40B

Предыдущая цена открытия

194.41

Предыдущая цена закрытия

195.62

Новостные настроения

By Acuity

67%

33%

291 / 340 Рейтинг в Healthcare

REVOLUTION Medicines Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 авг. 2026 г., 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 июл. 2026 г., 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 июл. 2026 г., 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 июл. 2026 г., 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 июл. 2026 г., 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 июл. 2026 г., 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 июл. 2026 г., 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 июл. 2026 г., 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

21 июл. 2026 г., 17:16 UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

20 июл. 2026 г., 17:31 UTC

Social Media
News

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.

Сравнение c конкурентами

Изменение цены

REVOLUTION Medicines Inc Прогноз

Целевая цена

By TipRanks

10.23% рост

Прогноз на 12 месяцев

Средняя 201.12 USD  10.23%

Максимум 263 USD

Минимум 151 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для REVOLUTION Medicines Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

19 ratings

18

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

291 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat